Table 3 |
|||||||
|
Effect of intervention diets on cardiovascular risk variables at baseline, 8 weeks and 12 weeks of intervention |
|||||||
|
Variable |
Visit |
PED arm |
MED arm |
P value2 (Difference between arm) |
Adjusted P value3 |
||
|
|
|
||||||
|
Value (mean ± SE) |
Mean % change from baseline |
Value (mean ± SE) |
Mean % change from baseline |
||||
|
|
|||||||
|
Cholesterol (mmol/L) |
Baseline |
6.57 ± 0.15 |
6.67 ± 0.20 |
||||
|
8 weeks |
5.67 ± 0.22** |
-13.8% |
6.09 ± 0.25** |
-8.7% |
0.13 |
0.04 |
|
|
12 weeks |
5.59 ± 0.14** |
-14.5% |
6.27 ± 0.22* |
-6.3% |
0.03 |
0.04 |
|
|
TG (mmol/L) |
Baseline |
2.78 ± 0.22 |
2.37 ± 0.23 |
||||
|
8 weeks |
2.02 ± 0.25** |
-27.2% |
1.84 ± 0.17** |
-22.3% |
0.27 |
0.05 |
|
|
12 weeks |
1.86 ± 0.12** |
-35.2% |
2.09 ± 0.19 |
-14.3% |
0.03 |
0.01 |
|
|
HDL (mmol/L) |
Baseline |
0.98 ± 0.05 |
1.02 ± 0.05 |
||||
|
8 weeks |
0.99 ± 0.05 |
0.7% |
1.00 ± 0.04 |
-1.6% |
0.34 |
0.45 |
|
|
12 weeks |
1.05 ± 0.05* |
7.0% |
1.04 ± 0.05 |
2.7% |
0.18 |
0.21 |
|
|
LDL (mmol/L) |
Baseline |
4.39 ± 0.17 |
4.64 ± 0.20 |
||||
|
8 weeks |
3.78 ± 0.19** |
-16.8% |
4.24 ± 0.20** |
-9.8% |
0.11 |
0.19 |
|
|
12 weeks |
3.69 ± 0.12** |
-17.3% |
4.28 ± 0.17* |
-8.4% |
0.11 |
0.18 |
|
|
Non-HDL cholesterol (mmol/L) |
Baseline |
5.59 ± 0.14 |
5.65 ± 0.19 |
||||
|
8 weeks |
4.67 ± 0.20** |
-16.4% |
5.09 ± 0.25** |
10.0% |
0.19 |
0.03 |
|
|
12 weeks |
4.54 ± 0.14** |
-18.2% |
5.23 ± 0.22* |
-8.0% |
0.02 |
0.03 |
|
|
LDL particle number (nmol/L) |
Baseline |
1634 ± 57 |
1733 ± 84 |
||||
|
8 weeks |
1453 ± 63* |
-11.9% |
1618 ± 108 |
-6.6% |
0.24 |
0.19 |
|
|
12 weeks |
1455 ± 63* |
-11.9% |
1629 ± 109* |
-7.0% |
0.26 |
0.31 |
|
|
Chol/HDL |
Baseline |
6.9 ± 0.3 |
6.8 ± 0.3 |
||||
|
8 weeks |
5.9 ± 0.3** |
-14.3% |
6.2 ± 0.3** |
-9.0% |
0.13 |
0.09 |
|
|
12 weeks |
5.6 ± 0.3** |
-19.5% |
6.3 ± 0.4** |
-8.9% |
0.01 |
0.02 |
|
|
TG/HDL |
Baseline |
3.1 ± 1.7 |
2.5 ± 1.4 |
||||
|
8 weeks |
2.1 ± 1.3** |
-30.6% |
1.9 ± 0.9** |
-23.2% |
0.20 |
0.07 |
|
|
12 weeks |
1.9 ± 0.7** |
-42.7% |
2.1 ± 1.1 |
-17.6% |
0.02 |
0.01 |
|
|
apo A-I (g/L) |
Baseline |
1.94 ± 0.06 |
1.96 ± 0.07 |
||||
|
8 weeks |
1.89 ± 0.05 |
-2.5% |
1.88 ± 0.06 |
-3.9% |
0.32 |
0.30 |
|
|
12 weeks |
1.90 ± 0.06 |
-2.1% |
1.87 ± 0.06 |
-4.3% |
0.24 |
0.16 |
|
|
apo B (g/L) |
Baseline |
1.48 ± 0.05 |
1.50 ± 0.06 |
||||
|
8 weeks |
1.30 ± 0.05** |
-12.1% |
1.36 ± 0.06** |
-9.9% |
0.32 |
0.21 |
|
|
12 weeks |
1.21 ± 0.04** |
-17.5% |
1.36 ± 0.06** |
-9.9% |
0.09 |
0.14 |
|
|
apoB/apoA-I |
Baseline |
0.78 ± 0.03 |
0.78 ± 0.04 |
||||
|
8 weeks |
0.70 ± 0.03* |
-10.3% |
0.73 ± 0.04* |
-6.4% |
0.26 |
0.13 |
|
|
12 weeks |
0.66 ± 0.03** |
-15.4% |
0.75 ± 0.05* |
-6.3% |
0.07 |
0.08 |
|
|
Fasting Glucose (mmol/L) |
Baseline |
5.49 ± 0.10 |
5.63 ± 0.11 |
||||
|
8 weeks |
5.31 ± 0.11 |
-3.3% |
5.46 ± 0.10 |
-2.9% |
0.45 |
0.42 |
|
|
12 weeks |
5.39 ± 0.10 |
-2.2% |
5.41 ± 0.12* |
-4.8% |
0.85 |
0.92 |
|
|
Fasting Insulin (pmol/L) |
Baseline |
82.65 ± 8.33 |
110.43 ± 13.13 |
||||
|
8 weeks |
53.48 ± 4.58** |
-35.2% |
75.70 ± 10.42* |
-31.0% |
0.66 |
0.82 |
|
|
12 weeks |
60.42 ± 5.69** |
-26.8% |
88.90 ± 11.74* |
-22.3% |
0.59 |
0.74 |
|
|
HOMA1 |
Baseline |
3.0 ± 0.4 |
4.1 ± 0.6 |
||||
|
8 weeks |
1.8 ± 0.2** |
-38.9% |
2.7 ± 0.4* |
-32.6% |
0.63 |
0.81 |
|
|
12 weeks |
2.0 ± 0.2* |
-29.7% |
3.0 ± 0.5 |
-24.9% |
0.61 |
0.76 |
|
|
HbA1c % |
Baseline |
5.7 ± 0.1 |
6.0 ± 0.1 |
||||
|
8 weeks |
5.6 ± 0.1* |
-1.9% |
5.9 ± 0.1** |
-2.7% |
0.77 |
0.72 |
|
|
12 weeks |
5.6 ± 0.1** |
-2.6% |
5.8 ± 0.1** |
-3.8% |
0.82 |
0.87 |
|
|
|
|||||||
|
*Different from baseline, P < 0.05 **Different from baseline, P < 0.01 1HOMA score calculated as follows: [(insulin (pmol/L)*glucose (mmol/L))/135]. 2Comparing the values between arms using 1-sided unpaired t-test 3Adjusted for body weight, caloric intake, and carbohydrate intake |
|||||||
|
Lerman et al. Nutrition & Metabolism 2008 5:29 doi:10.1186/1743-7075-5-29 |
|||||||
